AdAlta Limited (ASX:1AD)
Australia
· Delayed Price · Currency is AUD 0.0050
+0.0010 (25.00%)
Apr 29, 2026, 3:58 PM AEST
AdAlta Revenue
AdAlta had revenue of 306.15K AUD in the half year ending December 31, 2025, a decrease of -73.14%. This brings the company's revenue in the last twelve months to 608.07K, down -37.51% year-over-year. In the fiscal year ending June 30, 2025, AdAlta had annual revenue of 677.01K, down -61.04%.
Revenue (ttm)
608.07K
Revenue Growth
-37.51%
P/S Ratio
20.97
Revenue / Employee
608.07K
Employees
1
Market Cap
12.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 677.01K | -1.06M | -61.04% |
| Jun 30, 2024 | 1.74M | -1.73M | -49.91% |
| Jun 30, 2023 | 3.47M | 715.56K | 25.99% |
| Jun 30, 2022 | 2.75M | -1.23M | -30.89% |
| Jun 30, 2021 | 3.98M | 156.64K | 4.09% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| Tissue Repair | 3.38M |
| Bio-Gene Technology | 390.63K |
| Biotron | -868.00 |
| Invex Therapeutics | 229.08K |
| Vectus Biosystems | 89.96K |
| Chimeric Therapeutics | 9.75M |
| Neurotech International | 7.07M |